IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Carcinoma, Hepatocellular
/ drug therapy
Cisplatin
/ administration & dosage
Female
Fluorouracil
/ administration & dosage
Forecasting
Genotype
Hepatic Artery
Humans
Infusions, Intra-Arterial
Interferon alpha-2
/ administration & dosage
Interferon-alpha
/ administration & dosage
Interferons
/ genetics
Liver Neoplasms
/ drug therapy
Male
Middle Aged
Polyethylene Glycols
/ administration & dosage
Polymorphism, Single Nucleotide
Prognosis
Propensity Score
Recombinant Proteins
/ administration & dosage
Survival Rate
Treatment Outcome
Hepatic arterial infusion chemotherapy, predictive factor, prognostic factor
Hepatocellular carcinoma
IL-28B genotype
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
28
07
2019
revised:
28
02
2020
accepted:
09
03
2020
pubmed:
18
3
2020
medline:
24
11
2020
entrez:
18
3
2020
Statut:
ppublish
Résumé
Single-nucleotide polymorphisms (SNPs) of the interleukin-28B (IL-28B) gene are associated with the effectiveness of interferon therapy for chronic hepatitis C infection. Whether the IL-28B genotype affects the course of treatment and the outcomes of patients with advanced hepatocellular carcinoma (HCC) is unknown. We detected the IL-28B SNP (rs8099917) using TaqMan PreDesigned SNP Genotyping Assays to assess the effects of the IL-28B genotype on treatment efficacy and prognosis of patients with advanced HCC treated with hepatic arterial infusion chemotherapy (HAIC) between September 2003 and January 2015. The study included 154 patients who received HAIC to treat advanced HCC, among which 27 (17.5%) had the minor genotype, IL-28B rs8099917 TG or GG, and the others had the major genotype, IL-28B rs8099917 TT. The objective response rates of patients with the minor or major genotype were 51.9% and 29.1% (P = 0.022), respectively. Multivariate analysis revealed that the minor genotype remained associated with the response to HAIC (odds ratio, 2.620; P = 0.026). The median overall survival of patients with major or minor genotypes was 14.1 and 16.9 months, respectively, and the overall survival of patients with the major genotype was significantly shorter than that of patients with the minor genotype (P = 0.027). Multivariate analysis revealed that the major genotype was an independent, unfavorable prognostic factor (hazard ratio, 1.720; P = 0.024). Consistent results were obtained in selected populations after propensity score matching analysis. The IL-28B SNP (rs8099917) will serve as a useful predictor of the outcomes of patients with advanced HCC treated with HAIC.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Single-nucleotide polymorphisms (SNPs) of the interleukin-28B (IL-28B) gene are associated with the effectiveness of interferon therapy for chronic hepatitis C infection. Whether the IL-28B genotype affects the course of treatment and the outcomes of patients with advanced hepatocellular carcinoma (HCC) is unknown.
METHODS
METHODS
We detected the IL-28B SNP (rs8099917) using TaqMan PreDesigned SNP Genotyping Assays to assess the effects of the IL-28B genotype on treatment efficacy and prognosis of patients with advanced HCC treated with hepatic arterial infusion chemotherapy (HAIC) between September 2003 and January 2015.
RESULTS
RESULTS
The study included 154 patients who received HAIC to treat advanced HCC, among which 27 (17.5%) had the minor genotype, IL-28B rs8099917 TG or GG, and the others had the major genotype, IL-28B rs8099917 TT. The objective response rates of patients with the minor or major genotype were 51.9% and 29.1% (P = 0.022), respectively. Multivariate analysis revealed that the minor genotype remained associated with the response to HAIC (odds ratio, 2.620; P = 0.026). The median overall survival of patients with major or minor genotypes was 14.1 and 16.9 months, respectively, and the overall survival of patients with the major genotype was significantly shorter than that of patients with the minor genotype (P = 0.027). Multivariate analysis revealed that the major genotype was an independent, unfavorable prognostic factor (hazard ratio, 1.720; P = 0.024). Consistent results were obtained in selected populations after propensity score matching analysis.
CONCLUSIONS
CONCLUSIONS
The IL-28B SNP (rs8099917) will serve as a useful predictor of the outcomes of patients with advanced HCC treated with HAIC.
Substances chimiques
interferon-lambda, human
0
Interferon alpha-2
0
Interferon-alpha
0
Recombinant Proteins
0
Polyethylene Glycols
3WJQ0SDW1A
Interferons
9008-11-1
peginterferon alfa-2b
G8RGG88B68
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1813-1820Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016; 66: 7-30.
Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin. Oncol. 2012; 39: 399-409.
Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63: 844-855.
Takizawa D, Kakizaki S, Sohara N et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig. Dis. Sci. 2007; 52: 3290-3295.
Kudo M. Molecular targeted agents for hepatocellular carcinoma: current status and future perspectives. Liver Cancer 2017; 6: 101-112.
Kaneko S, Ikeda K, Matsuzaki Y et al. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J. Gastroenterol. 2016; 51: 1011-1021.
Terashima T, Yamashita T, Arai K et al. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol. Res. 2014; 44: 1179-1185.
Terashima T, Yamashita T, Horii R et al. Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC Cancer 2016; 16: 338.
Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003; 4: 63-68.
Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
Fabris C, Falleti E, Cussigh A et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol. 2011; 54: 716-722.
Hodo Y, Honda M, Tanaka A et al. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin. Cancer Res. 2013; 19: 1827-1837.
Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
Terashima T, Yamashita T, Arai K et al. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Sci. 2016; 107: 1263-1269.
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45: 228-247.
Kalathil SG, Lugade AA, Miller A, Iyer R, Thanavala Y. PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight 2016; 1 pii:e86182.
Chang CJ, Yang YH, Chiu CJ et al. Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse ortholopic hepatocellular carcinoma. Int. J. Cancer 2018; 142: 1878-1889.
Kokudo N, Takemura N, Hasegawa K et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol. Res. 2019; 49: 1109-1113.
Choi JH, Chung WJ, Bae SH et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother. Pharmacol. 2018; 82: 469-478.
Terashima T, Yamashita T, Iida N et al. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol. Res. 2015; 45: 949-959.
Ramamurthy N, Marchi E, Ansari MA et al. Impact of IFNL4 genotype on interferon-stimulated gene expression during DAA therapy for hepatitis C. Hepatology 2018; 68: 859-871.
Hamming OJ, Terczyńska-Dyla E, Vieyres G et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 2013; 32: 3055-3065.